# US 2016/0354368 A1 · Topical formulations for delivery of hedgehog inhibitor compounds and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354368 A1
- Document ID: US20160354368A1
- Status: Published application
- Kind: A1
- Application number: 15/173,257
- Filed: 2016-06-03
- Published: 2016-12-08
- Earliest claimed: 2015-06-04
- Assignees: PellePharm, Inc.
- Applicants: PellePharm, Inc.
- Inventors: Marc Barry Brown; Cameron Robert Stevenson; Charles Rodney Greenaway Evans
- Web page: https://patentgrep.com/patent/US20160354368A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/7084: {Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 47/02: Inorganic compounds
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.

## Claims

### Claim 1

A composition, comprising:
a hedgehog inhibitor compound and a solvent system comprising (i) a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8 and (ii) a buffer or a fatty acid comprising between 13-22 carbon atoms, wherein the hedgehog inhibitor compound is present in the solvent system between about 0.1-10 wt %.

### Claim 2

A composition, comprising:
a hedgehog inhibitor compound and a solvent system, the hedgehog inhibitor having a saturation solubility in the solvent system of between about 2.5-8 wt % and the solvent system comprising between about 15-60 wt % of a monohydric primary alcohol and between about 10-50 wt % propylene glycol.

### Claim 3

A composition, comprising:
a hedgehog inhibitor compound and a solvent system comprising (i) a monohydric alcohol comprised of at least one of ethanol and benzyl alcohol and propylene glycol, the monohydric alcohol and propylene glycol in a w/w ratio of between about 0.9-1.8 and (ii) a buffer or a fatty acid comprising between 13-22 carbon atoms, wherein the hedgehog inhibitor compound is present in the solvent system between about 0.1-10 wt %.

### Claim 4

A composition, comprising:
a hedgehog inhibitor compound and a solvent system comprising (i) a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and (ii) a fused bicyclic ether having from 8-14 carbon atoms, wherein the hedgehog inhibitor compound is present in the solvent system between about 0.1-10 wt %.

### Claim 5

A composition, comprising:
a hedgehog inhibitor compound and a solvent system comprising (i) a ternary combination of low molecular weight aliphatic polyols having 2 or 3 hydroxyl groups and a lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 1.5 and 2.4 and (ii) a fused bicyclic ether having from 8-14 carbon atoms, wherein the hedgehog inhibitor compound is present in the solvent system between about 0.1-10 wt %.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1-5, wherein the monohydric alcohol is represented by the structure CnH2n—OH, where n is 1, 2, 3 or 4.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the monohydric alcohol additionally includes benzyl alcohol.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the solvent system further comprises diethylene glycol monoethyl ether.

### Claim 9 (depends on 6)

The composition of claim 6, wherein the hedgehog inhibitor is patidegib or itraconazole.

### Claim 10

A composition, comprising:
patidegib and a solvent system comprising (i) ethanol and propylene glycol in a w/w ratio of between about 0.9-1.8, (ii) diethylene glycol monoethyl ether, and (iii) a buffer, wherein the hedgehog inhibitor compound is present in the solvent system in an amount between about 0.1-10 wt %.

### Claim 11

A composition, consisting essentially of:
patidegib and a solvent system comprising ethanol and propylene glycol in a w/w ratio of between about 0.9-1.8, wherein the patidegib has a saturation solubility in the solvent system of between about 2.5-8 wt % and wherein formulation provides an in vitro concentration of patidegib in the dermis of greater than about 250 μM 48 hours after topical application.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the solvent system further comprises diethylene glycol monoethyl ether and a buffer.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the solvent system further comprises a fatty acid comprising between 13-22 carbon atoms.

### Claim 14 (depends on 11)

The composition of claim 11, wherein the solvent system further comprises benzyl alcohol.

### Claim 15

A composition, consisting essentially of:
patidegib and a solvent system consisting of ethanol and benzyl alcohol in a w/w ratio with propylene glycol of between about 0.9-1.8 and a saturated fatty acid comprising between 13-22 carbon atoms.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the saturated fatty acid is selected from myristic acid (C14), palmitic acid (C16), stearic acid (C18) and arachidic acid (C22).

### Claim 17 (depends on 15)

The composition of claim 15, wherein the saturated fatty acid is iso-stearic acid.

### Claim 18 (depends on 1)

A topical delivery system, comprising a composition according to claim 1.

### Claim 19 (depends on 18)

The topical delivery system of claim 18, further comprising a backing member and membrane joined to define a reservoir in which the composition is contained.

### Claim 20 (depends on 19)

The topical delivery system of claim 19, wherein the membrane is a non-rate controlling membrane.

### Claim 21 (depends on 1, 18)

A method for treating basal cell carcinoma, comprising:
providing a composition according to claim 1 or a topical delivery system according to claim 18, whereby said providing comprises instructions to topically apply the composition of the system and wherein said topically applying achieves intracutaneous delivery of the hedgehog inhibitor compound in an amount sufficient for treating basal cell carcinoma, with a non-therapeutic concentration of the compound present in the blood of the subject.

### Claim 22 (depends on 1, 18)

A method for treating basal cell carcinoma, comprising:
topically applying a composition according to claim 1 or a topical delivery system according to claim 18 to a subject in need thereof, whereby said topically applying achieves intracutaneous delivery of the hedgehog inhibitor compound in an amount sufficient for treating basal cell carcinoma, with a non-therapeutic concentration of the compound present in the blood of the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the subject has Gorlin syndrome.
